1. Home
  2. TRGP vs RMD Comparison

TRGP vs RMD Comparison

Compare TRGP & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Targa Resources Inc.

TRGP

Targa Resources Inc.

HOLD

Current Price

$182.49

Market Cap

38.8B

Sector

Utilities

ML Signal

HOLD

Logo ResMed Inc.

RMD

ResMed Inc.

HOLD

Current Price

$245.15

Market Cap

36.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRGP
RMD
Founded
2005
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Natural Gas Distribution
Medical/Dental Instruments
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.8B
36.4B
IPO Year
2010
1995

Fundamental Metrics

Financial Performance
Metric
TRGP
RMD
Price
$182.49
$245.15
Analyst Decision
Strong Buy
Buy
Analyst Count
14
13
Target Price
$212.00
$289.09
AVG Volume (30 Days)
1.5M
924.4K
Earning Date
11-05-2025
01-29-2026
Dividend Yield
2.19%
0.98%
EPS Growth
34.09
29.59
EPS
7.42
9.77
Revenue
$17,378,100,000.00
$5,257,400,000.00
Revenue This Year
$12.14
$9.85
Revenue Next Year
$29.94
$7.36
P/E Ratio
$24.66
$25.05
Revenue Growth
7.17
9.36
52 Week Low
$144.14
$199.92
52 Week High
$218.51
$293.81

Technical Indicators

Market Signals
Indicator
TRGP
RMD
Relative Strength Index (RSI) 57.35 43.12
Support Level $176.18 $241.66
Resistance Level $185.35 $247.45
Average True Range (ATR) 4.27 4.94
MACD -0.36 -0.28
Stochastic Oscillator 56.26 18.66

Price Performance

Historical Comparison
TRGP
RMD

About TRGP Targa Resources Inc.

Targa Resources is a midstream firm that primarily operates gathering and processing assets with substantial positions in the Permian, Stack, Scoop, and Bakken plays. It has fractionation capacity at Mont Belvieu and operates a liquefied petroleum gas export terminal. The Grand Prix natural gas liquids pipeline is another important asset.

About RMD ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Share on Social Networks: